Cover Image

Partnerships, Licensing, Investments and M&A Deals and Trends for April 2015 in Pharmaceuticals

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for April 2015 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in April 2015. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner
  • Find out the major deal performing segments for investments in your industry
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry
  • Identify growth segments and opportunities in each region within the industry
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 6
  • 1.2 List of Figures 9

2 Pharmaceuticals & Healthcare, Global, Deal Summary 12

  • 2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, April 2015 12
  • 2.2 Pharmaceuticals & Healthcare, Global, Major Deals, April 2015 14
    • 2.2.1 Mylan to Acquire Perrigo 14
    • 2.2.2 Daiichi Sankyo Raises USD3.6 Billion in Public Offering of Shares of Sun Pharma 15
    • 2.2.3 Ventas to Acquire Ardent Medical Services for USD1.75 Billion 16
    • 2.2.4 DaVita HealthCare Prices Public Offering of 5% Notes Due 2025 for USD1.5 Billion 16
    • 2.2.5 Innate Pharma Enters into Co-Development Agreement with AstraZeneca for Immuno-Oncology 18
  • 2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, April 2015 19
  • 2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, April 2015 20

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 21

  • 3.1 Pharmaceuticals & Healthcare, Global, M&A, April 2015 21
    • 3.1.1 Top M&A Deals in April 2015 22
    • 3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, November 2014 - April 2015 23
  • 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, April 2015 25
    • 3.2.1 Top Equity Offering Deals in April 2015 26
    • 3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, November 2014 - April 2015 27
  • 3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, April 2015 29
    • 3.3.1 Top PE/VC Deals in April 2015 30
    • 3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, April 2015 31
    • 3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, April 2015 32
    • 3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, November 2014-April 2015 34
    • 3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, November 2014-April 2015 35

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, April 2015 36

  • 4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, April 2015 36
  • 4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, November 2014 - April 2015 38
  • 4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), April 2015 40
    • 4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, April 2015 41
  • 4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), November 2014 - April 2015 42
  • 4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, November 2014 - April 2015 44
  • 4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), November 2014 - April 2015 45
  • 4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), November 2014 - April 2015 47

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, April 2015 49

  • 5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, April 2015 49
  • 5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2015 51
  • 5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), November 2014 - April 2015 53
  • 5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), November 2014 - April 2015 55
  • 5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), November 2014 - April 2015 57
  • 5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), November 2014 - April 2015 60
    • 5.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, April 2015 61
    • 5.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, April 2015 62
    • 5.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, April 2015 62

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 63

  • 6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, April 2015 63
    • 6.1.1 Oncology - Deals of the Month 65
  • 6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, April 2015 67
    • 6.2.1 Central Nervous System - Deals of the Month 69
  • 6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, April 2015 70
    • 6.3.1 Infectious Diseases - Deals of the Month 72
  • 6.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, April 2015 73
    • 6.4.1 Cardiovascular - Deals of the Month 74
  • 6.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, April 2015 76
    • 6.5.1 Immunology - Deal of the Month 77
  • 6.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, April 2015 78
    • 6.6.1 Gastrointestinal - Deals of the Month 80
  • 6.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, April 2015 81
    • 6.7.1 Metabolic Disorders - Deal of the Month 83

7 Deal Summary by Geography 84

  • 7.1 Pharmaceuticals & Healthcare, North America Deals, April 2015 84
    • 7.1.1 North America - Deals of the Month 86
  • 7.2 Pharmaceuticals & Healthcare, Europe, Deals, April 2015 88
    • 7.2.1 Europe - Deals of the Month 90
  • 7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, April 2015 93
    • 7.3.1 Asia-Pacific - Deals of the Month 95
  • 7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, April 2015 96
    • 7.4.1 Rest of the World - Deals of the Month 98

8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 99

  • 8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, November 2014 - April 2015 99
  • 8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, November 2014 - April 2015 101

9 Further Information 103

  • 9.1 Methodology 103
  • 9.2 About GlobalData 104
  • 9.3 Disclosure information 105
  • 9.4 Disclaimer 105

List of Tables

1.1 List of Tables

  • Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 13
  • Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, April 2015 14
  • Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), April 2015 20
  • Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 22
  • Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, April 2015 22
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2014 - April 2015 24
  • Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 26
  • Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, April 2015 26
  • Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 28
  • Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 30
  • Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, April 2015 30
  • Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, November 2014 - April 2015 32
  • Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), April 2015 33
  • Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 34
  • Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, November 2014 - April 2015 35
  • Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 37
  • Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 39
  • Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2014 - April 2015 41
  • Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), April 2015 41
  • Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2014 - April 2015 43
  • Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2014 - April 2015 46
  • Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), November 2014 - April 2015 48
  • Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 50
  • Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), November 2014 - April 2015 52
  • Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 54
  • Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), April 2015 56
  • Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2014 - April 2015 59
  • Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), April 2015 61
  • Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, April 2015 61
  • Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, April 2015 62
  • Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, April 2015 62
  • Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 64
  • Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 68
  • Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 71
  • Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 74
  • Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 77
  • Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 79
  • Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 82
  • Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 85
  • Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 89
  • Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 94
  • Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 97
  • Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 100
  • Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 102

List of Figures

1.2 List of Figures

  • Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 12
  • Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), April 2015 19
  • Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), April 2015 20
  • Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 21
  • Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2014 - April 2015 23
  • Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 25
  • Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 27
  • Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 29
  • Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2014 - April 2015 31
  • Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), April 2015 32
  • Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), April 2015 33
  • Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 34
  • Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 36
  • Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 38
  • Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2014 - April 2015 40
  • Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2014 - April 2015 42
  • Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2014 - April 2015 44
  • Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2014 - April 2015 45
  • Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), November 2014 - April 2015 47
  • Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 49
  • Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2014 - April 2015 51
  • Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 53
  • Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2014 - April 2015 55
  • Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, November 2014 - April 2015 57
  • Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), November 2014 - April 2015 58
  • Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), April 2015 60
  • Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 63
  • Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 67
  • Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 70
  • Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 73
  • Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 76
  • Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 78
  • Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 81
  • Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 84
  • Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 88
  • Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 93
  • Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 96
  • Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 99
  • Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), November 2014 - April 2015 101
Show More
Pricing
  • Int'l: +1-860-674-8796
  • TollFree(US): +1-866-353-3335
  • Europe: +32-2-535-7543
  • Asia: +65-6223-2436
Back to Top